India-Latin America trade and collaboration prospects discussed at Kerala University conference

A panel discussion on ‘India-Latin America Business Prospects’ was held at the University of Kerala on Friday as part of the Centre for Latin American Studies (CLAS) international conference on the topic ‘Partners in Progress: Enhancing Synergies and Complementarities between India and Latin America’.

The session saw a convergence of scholars, diplomats, and experts in the field of India-Latin America relations, who shared their insights on the growing trade and business prospects between the regions.
Pablo Kunik, an economist from Argentina, opened the discussion by providing an overview of the expanding multilateral trade relations between India and Latin America. He highlighted the success of Indian companies such as Tata Motors and Mahindra in Latin American markets, especially Brazil and Mexico.

Dr. Kunik focused on the bilateral trade between India and Argentina, observing that trade had surged to approximately $3.2 billion in 2023. India exports pharmaceuticals, automobiles, textiles, machinery and IT services to Argentina, while Argentina sends agricultural products, including soybeans and meat to India.

G. Levin, chief executive officer of K-Space, spoke about the potential for India’s collaboration with Latin American countries, especially in space research. Highlighting the advantages of Latin America’s proximity to the equator, Mr. Levin emphasised how the Indian Space Research Organisation could extend its services to Latin America, further strengthening the region’s space capabilities.

Former diplomat R. Viswanathan, a Latin America expert and CLAS executive council member, also shared success stories of Indian companies in Latin America, such as Tata Consultancy Services (TCS) in Uruguay, and stressed the growing economic collaboration. He noted that such partnerships represent a new paradigm of business between India and Latin America, benefiting both regions in numerous sectors, including IT, energy and manufacturing.

Godavarthi Venkata Srinivas, Additional Secretary of the Latin America and Caribbean Division in the Ministry of External Affairs chaired the session.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’